Zia Rahman, MD
Hematology & Oncology · Hartford, CTNPI 1417950494
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $1,000 of the $1,170 with a category attached, or 85.5%. Puma Biotechnology, Inc. accounts for 96.1% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2019 at $1,125 and has fallen 98.0% since, to $22 in 2024. That places this record below the midpoint for hematology & oncology clinicians in CT, where the typical reported total is $1,376.
Across 5 payments — averaging $234.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Puma Biotechnology, Inc.$1K
- Hydrofera LLC$22
- Gilead$12
- E.r. Squibb & Sons, L.L.C.$11
Across 63 payments — averaging $4851.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Daiichi Sankyo Inc.$154K
- AstraZeneca$87K
- Astrazeneca UK Limited$37K
- Puma Biotechnology, Inc.$27K
What the payments were for
- Consulting fees$1,00085%
- Food & beverage$14713%
- Education$232%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Puma Biotechnology, Inc. | 2 | $1,125 |
| Hydrofera LLC | 1 | $22 |
| Gilead | 1 | $12 |
| E.r. Squibb & Sons, L.L.C. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Nerlynx$1,125
How this compares
$1,170 in reported general payments places this provider in the 45th percentile of 163 hematology & oncology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 59 | $913,830 |
| VerzenioAbemaciclib | 55 | $823,736 |
| Anastrozole | 294 | $4,536 |
| Exemestane | 21 | $4,468 |
| Letrozole | 124 | $2,745 |
| Tamoxifen Citrate | 85 | $2,444 |
| Duloxetine Hcl | 18 | $1,176 |
| Gabapentin | 13 | $282 |
| Prochlorperazine Maleate | 20 | $278 |
| Oxybutynin Chloride | 14 | $223 |
| Dexamethasone | 11 | $204 |
| Potassium Chloride | 13 | $111 |
| Nystatin | 11 | $100 |
| Lorazepam | 38 | $92 |
| Ondansetron Hcl | 13 | $90 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Hartford
- Madhavi GorusuHartford$207K
- Adam BoruchovHartford$55K
- Shabnam RehmanHartford$25K
- Todd AlekshunHartford$22K
- Yelena PristyazhnyukHartford$9K
- Kin Wai HungHartford$7K
- Stephen FirsheinHartford$7K
- Paul DekkerHartford$6K
- Amer ZeidanNew Haven$807K
- Biree AndemariamFarmington$646K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.